Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Baumgartner

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The European Respiratory Journal|November 4, 2008
Inhalation of vasoactive intestinal peptide in pulmonary hypertensionH H Leuchte, C Baezner, R A Baumgartner, et al.
Molecular Biology of the Cell|April 1, 1994
Studies with transfected and permeabilized RBL-2H3 cells reveal unique inhibitory properties of protein kinase C gammaR A Baumgartner, K Ozawa, J R Cunha-Melo, et al.
COPD|March 11, 2010
The safety and efficacy of arformoterol and formoterol in COPDNicola A Hanania, James F Donohue, Harold Nelson, et al.
Therapeutic Advances in Respiratory Disease|January 7, 2009
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and toleranceJ F Donohue, N A Hanania, K A Sciarappa, et al.
Thorax|March 18, 2000
Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patientsR J Dockhorn, R A Baumgartner, J A Leff, et al.
Pulmonary Pharmacology & Therapeutics|May 27, 2008
A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary diseaseJ Kharidia, C M Fogarty, C F Laforce, et al.
The European Respiratory Journal|February 7, 2003
Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasoneR A Baumgartner, G Martinez, J M Edelman, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The European Respiratory Journal|November 4, 2008
Inhalation of vasoactive intestinal peptide in pulmonary hypertensionH H Leuchte, C Baezner, R A Baumgartner, et al.
Molecular Biology of the Cell|April 1, 1994
Studies with transfected and permeabilized RBL-2H3 cells reveal unique inhibitory properties of protein kinase C gammaR A Baumgartner, K Ozawa, J R Cunha-Melo, et al.
COPD|March 11, 2010
The safety and efficacy of arformoterol and formoterol in COPDNicola A Hanania, James F Donohue, Harold Nelson, et al.
Therapeutic Advances in Respiratory Disease|January 7, 2009
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and toleranceJ F Donohue, N A Hanania, K A Sciarappa, et al.
Thorax|March 18, 2000
Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patientsR J Dockhorn, R A Baumgartner, J A Leff, et al.
Pulmonary Pharmacology & Therapeutics|May 27, 2008
A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary diseaseJ Kharidia, C M Fogarty, C F Laforce, et al.
The European Respiratory Journal|February 7, 2003
Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasoneR A Baumgartner, G Martinez, J M Edelman, et al.
Pageof 2